Latest News
InnoCare reports first patient dosed in Phase II/III vitiligo trial
16 May 2025 - Biopharmaceutical company InnoCare Pharma (HKEX:09969) (SSE:688428) reported on Friday that the first patient has been dosed in a Phase II/III clinical trial of Soficitinib (ICP-332) for the treatment of non-segmental vitiligo in China....
Oxurion to acquire 72% stake in French biometrics firm Axiodis CRO
16 May 2025 - Belgian biopharmaceutical company Oxurion NV (Euronext Brussels:OXUR) announced on Friday that it has signed a binding agreement to acquire 72% of French biometrics specialist Axiodis CRO through its French subsidiary, Oxurion France.Un...
Rznomics and Eli Lilly agree global licensing deal for RNA-editing therapeutics
16 May 2025 - Rznomics Inc, a South Korean biopharmaceutical company specialising in RNA-based therapeutics, announced on Thursday that it has entered into a strategic global research collaboration and licensing agreement with Eli Lilly and Company (...
SparX Biopharmaceutical and Mitsubishi Tanabe Pharma America collaborate to research novel ADCs
16 May 2025 - Clinical-stage biotechnology company SparX Biopharmaceutical Corp announced on Thursday that it has entered into a research agreement with Mitsubishi Tanabe Pharma America Inc (MTPA).The collaboration aims to advance an antibody-drug co...
Endo adds new concentration to ADRENALIN ready-to-use premixed bag line
16 May 2025 - Pharmaceutical company Endo Inc (OTCQX: NDOI) announced Thursday the launch of ADRENALIN (epinephrine in 0.9% sodium chloride injection) 8 mg/250 mL premixed bag, and will begin distribution from the week of 19 May 2025.ADRENALIN is the...